Mitsubishi Tanabe Pharma
Research-driven pharmaceutical company conducting discovery, development, manufacturing, regulatory submissions, and global commercialization across small molecules, biologics, vaccines, gene/cell therapies and drug-delivery systems. Operates global R&D and clinical development programs, maintains manufacturing and vaccine production partnerships, and publishes clinical-trial information and sustainability reporting.
Industries
Nr. of Employees
Very Large (1000+)
Mitsubishi Tanabe Pharma
Products
Radicava (Edaravone)
A drug for treating amyotrophic lateral sclerosis (ALS) that acts as a free radical scavenger to protect nerve cells.
CANAGLU Tablets 100mg
An oral medication that inhibits sodium glucose co-transporter 2 (SGLT2) to treat type 2 diabetes mellitus.
UPLIZNA (Inebilizumab)
An anti-CD19 monoclonal antibody for intravenous infusion used to treat neuromyelitis optica spectrum disorder (NMOSD).
Zepbound
A long-acting GIP/GLP-1 receptor agonist for treating obesity disease with multiple factors.
CANALIA Combination OD Tablets
A combination oral drug containing selective DPP-4 inhibitor and SGLT2 inhibitor for type 2 diabetes mellitus treatment.
Alesion Eyelid Cream 0.5%
A topical cream for once-daily treatment of allergic conjunctivitis applied to upper and lower eyelids.
Radicava (Edaravone)
A drug for treating amyotrophic lateral sclerosis (ALS) that acts as a free radical scavenger to protect nerve cells.
CANAGLU Tablets 100mg
An oral medication that inhibits sodium glucose co-transporter 2 (SGLT2) to treat type 2 diabetes mellitus.
UPLIZNA (Inebilizumab)
An anti-CD19 monoclonal antibody for intravenous infusion used to treat neuromyelitis optica spectrum disorder (NMOSD).
Zepbound
A long-acting GIP/GLP-1 receptor agonist for treating obesity disease with multiple factors.
CANALIA Combination OD Tablets
A combination oral drug containing selective DPP-4 inhibitor and SGLT2 inhibitor for type 2 diabetes mellitus treatment.
Alesion Eyelid Cream 0.5%
A topical cream for once-daily treatment of allergic conjunctivitis applied to upper and lower eyelids.
Services
Discovery and preclinical-to-clinical development across therapeutic areas and modalities delivered through internal programs and external collaborations.
Manufacture and supply of prescription medicines, biologics and vaccines via company facilities and manufacturing partnerships to support commercial distribution.
Out-licensing, in-licensing, co-development and co-promotion arrangements for regional and global markets, including regulatory and market-access support.
Controlled sharing of anonymized clinical trial datasets with qualified researchers under review and governance, and maintenance of public clinical-trial registries and disclosure summaries.
Discovery and preclinical-to-clinical development across therapeutic areas and modalities delivered through internal programs and external collaborations.
Manufacture and supply of prescription medicines, biologics and vaccines via company facilities and manufacturing partnerships to support commercial distribution.
Out-licensing, in-licensing, co-development and co-promotion arrangements for regional and global markets, including regulatory and market-access support.
Controlled sharing of anonymized clinical trial datasets with qualified researchers under review and governance, and maintenance of public clinical-trial registries and disclosure summaries.
Expertise Areas
- Clinical trial management and disclosure
- Multimodal drug discovery (small molecules, biologics, ADCs)
- Vaccine research and development
- Gene and cell therapy R&D
Key Technologies
- Monoclonal antibody development
- Antibody‑drug conjugates (ADC)
- Virus‑like particle (VLP) vaccines
- Plant-based vaccine production methods
News & Updates
Regulatory approval in Japan for an additional indication relating to suppression of relapse of immunoglobulin G4‑related disease (news release).
Company received a Complete Response Letter from the U.S. FDA related to an investigational continuous subcutaneous levodopa/carbidopa infusion program.
Submission of an application in Japan seeking an additional indication for a CD19‑targeting monoclonal antibody for generalized Myasthenia Gravis.
Announcement of initiation of a Phase 1/2 clinical trial for a BRD4 degrader program in advanced solid tumors.
Regulatory submissions and interactions with FDA and EMA for a continuous subcutaneous infusion program for motor fluctuations in Parkinson's disease.
Regulatory approval in Japan for an additional indication relating to suppression of relapse of immunoglobulin G4‑related disease (news release).
Company received a Complete Response Letter from the U.S. FDA related to an investigational continuous subcutaneous levodopa/carbidopa infusion program.
Submission of an application in Japan seeking an additional indication for a CD19‑targeting monoclonal antibody for generalized Myasthenia Gravis.
Announcement of initiation of a Phase 1/2 clinical trial for a BRD4 degrader program in advanced solid tumors.
Regulatory submissions and interactions with FDA and EMA for a continuous subcutaneous infusion program for motor fluctuations in Parkinson's disease.